Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year. Despite these beats, the market responded negatively, reflecting concerns raised by management about continued macro and competitive pressures. CEO Chris Boerner pointed to strong demand across the company’s growth portfolio, especially in oncology and hematology, while also acknowledging regulatory wins and cost optimization initiatives. The quarter was further shaped by the launch of new therapies and an increased focus on reshaping the business for long-term growth.
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts’ consensus estimates.
Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance to a robust showing across its commercial portfolio, especially in oncology, vaccines, and rare disease products. CEO Albert Bourla highlighted that disciplined cost control and productivity enhancements—including expanded use of automation and AI—contributed to improved operating margins. The company also benefited from higher-than-anticipated demand for several newly launched products and continued international momentum, particularly for its Vyndaqel family and key oncology brands.
Pfizer, Inc. stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be around $13.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.62 per share was 11.6% above analysts’ consensus estimates.
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on global economies. The U.S. presidential election, a quadrennial event of immense significance, consistently introduces periods of heightened uncertainty and volatility, often culminating
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary
